Sarepta Other Operating Expenses from 2010 to 2024

SRPT Stock  USD 126.66  2.14  1.66%   
Sarepta Therapeutics Other Operating Expenses yearly trend continues to be comparatively stable with very little volatility. Other Operating Expenses is likely to outpace its year average in 2024. Other Operating Expenses is expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production. View All Fundamentals
 
Other Operating Expenses  
First Reported
1996-03-31
Previous Quarter
352.7 M
Current Value
372.2 M
Quarterly Volatility
118.2 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Sarepta Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Sarepta main balance sheet or income statement drivers, such as Depreciation And Amortization of 61.8 M, Interest Expense of 23.1 M or Selling General Administrative of 506 M, as well as many exotic indicators such as Price To Sales Ratio of 6.81, Dividend Yield of 0.0 or PTB Ratio of 6.7. Sarepta financial statements analysis is a perfect complement when working with Sarepta Therapeutics Valuation or Volatility modules.
  
This module can also supplement Sarepta Therapeutics' financial leverage analysis and stock options assessment as well as various Sarepta Therapeutics Technical models . Check out the analysis of Sarepta Therapeutics Correlation against competitors.
For more information on how to buy Sarepta Stock please use our How to Invest in Sarepta Therapeutics guide.

Latest Sarepta Therapeutics' Other Operating Expenses Growth Pattern

Below is the plot of the Other Operating Expenses of Sarepta Therapeutics over the last few years. Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Sarepta Therapeutics. It is also known as Sarepta Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. It is expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production. Sarepta Therapeutics' Other Operating Expenses historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Sarepta Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Other Operating Expenses10 Years Trend
Slightly volatile
   Other Operating Expenses   
       Timeline  

Sarepta Other Operating Expenses Regression Statistics

Arithmetic Mean637,523,333
Geometric Mean293,888,986
Coefficient Of Variation92.75
Mean Deviation521,080,756
Median297,795,000
Standard Deviation591,297,780
Sample Variance349633.1T
Range1.6B
R-Value0.96
Mean Square Error30793.5T
R-Squared0.92
Slope126,696,311
Total Sum of Squares4894862.9T

Sarepta Other Operating Expenses History

20241.6 B
20231.5 B
20221.5 B
20211.2 B
20201.1 B
2019903.2 M
2018644.7 M

About Sarepta Therapeutics Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Sarepta Therapeutics income statement, its balance sheet, and the statement of cash flows. Sarepta Therapeutics investors use historical funamental indicators, such as Sarepta Therapeutics's Other Operating Expenses, to determine how well the company is positioned to perform in the future. Although Sarepta Therapeutics investors may use each financial statement separately, they are all related. The changes in Sarepta Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Sarepta Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Sarepta Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Sarepta Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Other Operating Expenses1.5 B1.6 B

Currently Active Assets on Macroaxis

When determining whether Sarepta Therapeutics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Sarepta Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Sarepta Therapeutics Stock. Highlighted below are key reports to facilitate an investment decision about Sarepta Therapeutics Stock:
Check out the analysis of Sarepta Therapeutics Correlation against competitors.
For more information on how to buy Sarepta Stock please use our How to Invest in Sarepta Therapeutics guide.
You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.

Complementary Tools for Sarepta Stock analysis

When running Sarepta Therapeutics' price analysis, check to measure Sarepta Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sarepta Therapeutics is operating at the current time. Most of Sarepta Therapeutics' value examination focuses on studying past and present price action to predict the probability of Sarepta Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sarepta Therapeutics' price. Additionally, you may evaluate how the addition of Sarepta Therapeutics to your portfolios can decrease your overall portfolio volatility.
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
CEOs Directory
Screen CEOs from public companies around the world
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Is Sarepta Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sarepta Therapeutics. If investors know Sarepta will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sarepta Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(5.80)
Revenue Per Share
13.456
Quarterly Revenue Growth
0.535
Return On Assets
(0.05)
Return On Equity
(0.86)
The market value of Sarepta Therapeutics is measured differently than its book value, which is the value of Sarepta that is recorded on the company's balance sheet. Investors also form their own opinion of Sarepta Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sarepta Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sarepta Therapeutics' market value can be influenced by many factors that don't directly affect Sarepta Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sarepta Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sarepta Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sarepta Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.